Investigation of LINC00342 as a poor prognostic biomarker for human patients with non–small cell lung cancer

Abstract

Cyclic long noncoding RNAs have recently become major players in cancer biology and can serve as biomarkers for cancer diagnosis and prognosis, and as potential therapeutic targets. We explored circulating LINC00342 as a predictor of non–small cell lung cancer (NSCLC). The expression of LINC00342 in tissues, serum, PBMC, and NSCLC cell lines were screened by reverse transcription quantitative polymerase chain reaction. A multistage validation and risk score formula detection analysis was used. The effect of LINC00342 on proliferation was assessed by MTT, p53, and PTEN pathways, which were analyzed by Western blot analysis. We found that LINC00342 was upregulated in the tissues, serum, and PBMC of patients with NSCLC. In addition, patients with higher LINC00342 expression levels were associated with poor overall survival. For the diagnosis of NSCLC, the specificity and sensitivity of LINC00342 were significantly higher than that of CYFRA 21‐1. Moreover, LINC00342 promoted proliferation by inhibiting the expression of p53 and PTEN proteins in NSCLC cell lines. Our study demonstrates that LINC00342 is involved in the development, and LINC00342 may be a potential diagnostic factor and a target for new therapies for future patients with NSCLC.

LncRNA LINC00342 contributes to the growth and metastasis of colorectal cancer via targeting miR-19a-3p/NPEPL1

“…LINC00342, a novel lncRNA located on chromosome 2q11.1, was upregulated in non-small cell lung cancer (NSCLC) and infantile hemangiomas [12,13]. High expression of LINC00342 predicted a poor prognosis in NSCLC [14]. Knockdown of LINC00342 inhibited NSCLC cell proliferation, migration and invasion [15].…”

MiRNAs and LncRNAs: Dual Roles in TGF-β Signaling-Regulated Metastasis in Lung Cancer

“…MiRNAs and lncRNAs can be detected in biological fluids through a biopsy of liquids, such as whole blood (lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) [141] and miRNA-182-5p [142]), serum (lncRNA linc00342 [143], MEG3 [144], miR-96 [145] and miR-30a-5p [146]), plasma (lncRNA linc00152 [147], MALAT1 [148], miR-145 [149], miR-30b [150], miR-25 [151] and miR-425-3p [152]), sputum (lncRNA HOTAIR, H19 [153], miR-21 and miR-210 [154]), and pleural effusion (MALAT1 [155] and miR-200 family [156]) in lung cancer. Furthermore, miRNAs can also be found in bronchoalveolar lavage fluid (miR-126 and miR-Let-7a [157]).…”

LncRNA LINC00342 contributes to the growth and metastasis of colorectal cancer via targeting miR-19a-3p/NPEPL1

“…LINC00342, a novel lncRNA located on chromosome 2q11.1, is up-regulated in non-small cell lung cancer (NSCLC) and infantile hemangiomas [24,25]. High expression of LINC00342 predicts a poor prognosis in NSCLC [26]. Knockdown of LINC00342 inhibits NSCLC cell proliferation, migration and invasion [27].…”